Atlas market file · Equity · United States
AtaiBeckley Inc.ATAI
- Last close
- 7.18
- Change
- -0.55%
- 96-bar range
- 3.265 – 7.22
- As of
- 6 Aug 2026
AtaiBeckley Inc. is a pharmaceutical preparations issuer listed as ATAI on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ATAI
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+448.09% over the window).
Source rail: Yahoo Finance chart API (ATAI). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ATAI. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ATAI public profile
Pharmaceutical preparations issuer. AtaiBeckley Inc. is connected to current market context, cited company sources and its retained research file.
AtaiBeckley Inc. trades as ATAI on NASDAQ. AtaiBeckley Inc. (ATAI) has a latest verified close of 7.18, down 0.55%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ATAI under USA Stocks and Technology Stocks for browsing.
What changed for AtaiBeckley Inc. today
AtaiBeckley Inc. (ATI) announced a definitive merger agreement with Eli Lilly on July 16, 2026, under which Lilly will acquire all outstanding AtaiBeckley shares for $6.75 in cash plus a non-transferable contingent value right (CVR) per share, contingent on future regulatory and development milestones. The deal, expected to close in Q3 2026 pending shareholder and regulatory approval, values the company at roughly $2.4B based on 357.4M diluted shares outstanding.
AtaiBeckley operates in the psychedelics-based therapeutics sector, focusing on DMT buccal film (VLS-01) and other clinical-stage assets. Its Q1 2026 financials reveal a company in flux: $954K revenue (likely nominal or related-party), $29.8M net loss, and $43.1M cash reserves burning at a $21.1M quarterly rate. The balance sheet shows $264.9M total assets but no meaningful capex, suggesting limited physical infrastructure despite the biotech veneer.
The merger filings reveal a board prioritizing exit over organic growth. R&D spend remains minimal ($600K Q1), while insider transactions and governance filings show heightened executive option grants ahead of the deal. The CVR structure transfers development risk to legacy shareholders, who must now bet on Lilly’s ability to navigate FDA pathways for compounds AtaiBeckley couldn’t advance alone.
Chart context is absent from the evidence pack, but the merger arbitrage trade hinges on regulatory timelines and CVR terms. The source directs readers to SEC filings for proxy solicitations and Lilly’s integration plans. The lack of disclosed revenue from commercial operations-and the absence of near-term catalysts outside the merger-leaves little fundamental support if the deal falters.
Risks include merger breakdown (shareholder dissent, regulatory block), continued cash burn outpacing development timelines, and CVR milestones proving unachievable. Catalysts center on merger approval, interim data from Lilly’s inherited programs, and potential secondary deals for AtaiBeckley’s remaining pipeline assets.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ATAI technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ATAI
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ATAI research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ATAI FAQ
What is AtaiBeckley Inc. (ATAI)?AtaiBeckley Inc. (ATAI) has a latest verified close of 7.18, down 0.55%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
AtaiBeckley Inc. (ATAI) has a latest verified close of 7.18, down 0.55%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ATAI?AtaiBeckley Inc. (ATAI) has a latest verified close of 7.18, down 0.55%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
AtaiBeckley Inc. (ATAI) has a latest verified close of 7.18, down 0.55%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ATAI under USA Stocks and Technology Stocks for browsing.
How often is the ATAI page updated?The ATAI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ATAI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ATAI?The ATAI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ATAI. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ATAI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ATAI. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ATAI?Yes. The workstation can open ATAI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ATAI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ATAI page investment advice?No. The ATAI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ATAI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →